Avicenna Holdings Limited has been acquired by Juno Health
The shareholders of Avicenna Holdings Limited have sold the business to Juno Health.
Based in the UK, Avicenna comprises 21 pharmacies, as well as a buying group operation serving more than 1,000 independent pharmacies.
Juno Health is a UK-based company that operates a chain of pharmacy stores. The community pharmacies will be integrated into Juno’s existing chain with the buying group continuing to be run by Salim Jetha, Avicenna CEO. It will become the industry-leading buying and support group for independent pharmacies across the UK. Juno has considerable experience in the sector and the combination of Avicenna resources and expertise will support the independent pharmacy sector and improve membership benefits.
Richard Smith, Chairman at Juno Health, said: “Avicenna is a well-established business delivering clear benefits to its members. It is one of the most recognizable brands among independent pharmacists and extremely well respected.”
Oaklins Cavendish, based in the UK, advised the shareholders of Avicenna on the sale of the business to Juno Health.
Talk to the deal team
Related deals
Parcom has sold Krifon to Varro
Krifon AS, a leading Nordic B2B distributor specializing in home and garden products, has been acquired by Varro. The transaction marks a new chapter for the company as it continues to strengthen its position as a trusted category partner to leading DIY chains, garden centers and furniture retailers in Norway.
Learn moreEbidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment
Ebidco S.r.l. has completed a voluntary public tender offer for the shares of Eles Semiconductor Equipment S.p.A.
Learn moreInstituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn more